CAR T-Cell Whitepaper
Overview
We teamed up with Quanterix to create a graphical abstract for their White Paper on their Simoa® assay and its ability to detect ultra-low levels of cytokines during CAR T-cell therapy. The infographic highlights how the Simoa® platform supports monitoring of cytokine release syndrome and neurotoxicity to improve the safety and success of cell therapy. The visual walks readers through the full CAR T-cell therapy process, from cell creation and infusion to cancer cell apoptosis and potential adverse effects.
What is CAR T-cell therapy?
CAR T-cell therapy is an immunotherapy treatment against cancer. T cells are a part of the immune system that are in charge of attacking foreign particles, such as cancer cells. However, cancer can often hide from its attackers. CAR T-cells are specially engineered lymphocytes that can recognize the particular antigen of the specific cancer and be used in immunotherapy. When immune cells are activated during the destruction of cancer cells, the body is flooded with a large amount of cytokines which can lead to cytokine release syndrome (CRS). These include life threatening symptoms such as hypertension, capillary leak, and cardiac dysfunction to name a few.
